综述:炎症性肠病的新兴药物治疗
该综述检索Pubmed、Medline和Cochrane数据库至2021年7月,并手动查阅灰色文献,总结炎症性肠病新兴药物的作用机制与临床试验数据。在溃疡性结肠炎中,S1P受体激动剂、抗IL-23药物、抗淋巴细胞 trafficking 药物、JAK抑制剂和TLR9激动剂的2b期和/或3期研究达到主要终点;在克罗恩病中,抗IL-23药物、JAK抑制剂和抗淋巴细胞 trafficking 药物在随机对照试验中达到主要终点。结论认为多种新药早期试验显示阳性疗效和安全性数据,仍需研究疗效预测因素和头对头试验。
要点
- 溃疡性结肠炎中S1P受体激动剂、抗IL-23药物、抗淋巴细胞转运药物、JAK抑制剂和TLR9激动剂的2b/3期研究达到主要终点。
- 克罗恩病中抗IL-23药物、JAK抑制剂和抗淋巴细胞转运药物在随机对照试验中达到主要终点。
- 多种炎症性肠病新药早期试验显示阳性疗效和安全性数据,仍需疗效预测因素研究和头对头试验。
核心结论
- 多种炎症性肠病新药治疗在早期临床试验中显示阳性疗效和安全性数据,治疗管线中仍有多种药物。
- 随着更多克罗恩病和溃疡性结肠炎治疗获批临床使用,需要评估疗效预测因素的研究和头对头试验,以指导提供者最佳定位炎症性肠病患者的治疗选择。
研究设计与样本
- 综述检索Pubmed、Medline和Cochrane数据库截至2021年7月,关键词包括「炎症性肠病」「IBD」「克罗恩病」「溃疡性结肠炎」及「试验」「期」「研究」。
- 手动查阅灰色文献,包括临床试验注册库和2020年及2021年主要消化病学会议摘要,以纳入相关信息。
主要发现
- 在溃疡性结肠炎中,S1P受体激动剂(estrasimod、ozanimod)、抗IL-23药物(mirikizumab)、抗淋巴细胞转运药物(ontamalimab、皮下vedolizumab)、JAK抑制剂(upadacitinib、filgotinib)和TLR9激动剂(cobitolimod)的2b期和/或3期研究达到主要终点。
- 在克罗恩病中,抗IL-23药物(risankizumab、mirikizumab、guselkumab)、JAK抑制剂(upadacitinib、filgotinib)和抗淋巴细胞转运药物(ontamalimab、etrolizumab)在随机对照临床试验中达到主要终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The landscape of inflammatory bowel disease (IBD) treatment is rapidly expanding with the development of new therapeutic options. AIM: To review the mechanisms of action and the available clinical trial data on emerging drug therapies for IBD. METHODS: Pubmed, Medline and Cochrane databases were queried up to July 2021 using keywords "inflammatory bowel disease," "IBD," "Crohn's disease," "ulcerative colitis" and "trial," "phase" and "study." In addition, we manually reviewed the grey literature including clinical trial registries and abstracts from major gastroenterology conferences in 2020 and 2021 to include pertinent information. RESULTS: In ulcerative colitis (UC), phase 2b and/or phase 3 studies met primary endpoints for S1P receptor agonists (estrasimod, ozanimod), anti-IL-23 agent (mirikizumab), anti-lymphocyte trafficking agents (ontamalimab, subcutaneous vedolizumab), JAK inhibitors (upadacitinib, filgotinib) and TLR9 agonist (cobitolimod). In Crohn's disease (CD), anti-IL-23 agents (risankizumab, mirikizumab, guselkumab), JAK inhibitors (upadacitinib, filgotinib) and anti-lymphocyte trafficking agents (ontamalimab, etrolizumab) met primary endpoints in randomised controlled clinical trials. CONCLUSION: Several new IBD drug therapies have positive efficacy and safety data in early clinical trials, and there are several drugs in the therapeutic pipeline. As more treatments for CD and UC are approved for clinical use, research to assess predictors of response to therapy and head-to-head trials is needed to inform providers on how to best position therapeutic options for patients with IBD.
引用
- Grossberg LB, Papamichael K, Cheifetz AS, et al. Review article: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35166398. doi:10.1111/apt.16785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。